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Abstract
Background: To determine the psychometric properties of the Hospital Anxiety and Depression
Scale (HADS) in patients with breast cancer and determine the suitability of the instrument for use
with this clinical group.
Methods: A cross-sectional design was used. The study used a pooled data set from three breast
cancer clinical groups. The dependent variables were HADS anxiety and depression sub-scale
scores. Exploratory and confirmatory factor analyses were conducted on the HADS to determine
its psychometric properties in 110 patients with breast cancer. Seven models were tested to
determine model fit to the data.
Results: Both factor analysis methods indicated that three-factor models provided a better fit to
the data compared to two-factor (anxiety and depression) models for breast cancer patients. Clark
and Watson's three factor tripartite and three factor hierarchical models provided the best fit.
Conclusion: The underlying factor structure of the HADS in breast cancer patients comprises
three distinct, but correlated factors, negative affectivity, autonomic anxiety and anhedonic
depression. The clinical utility of the HADS in screening for anxiety and depression in breast cancer
patients may be enhanced by using a modified scoring procedure based on a three-factor model of
psychological distress. This proposed alternate scoring method involving regressing autonomic
anxiety and anhedonic depression factors onto the third factor (negative affectivity) requires
further investigation in order to establish its efficacy.
Background
A diagnosis of breast cancer is often accompanied by a sig-
nificant and profound experience of psychological dis-
tress, the most commonly presenting symptoms being
those of anxiety and depression [1]. Indeed, prevalence
rates of clinically relevant levels of anxiety and depression
in cancer patients have been estimated to be up to 45% [2-
4]. It has been observed that psychological symptoms
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in the clinical presentation of breast cancer that up to 30%
of these patients will continue to experience clinically rel-
evant levels of anxiety and depression at follow-up [5].
The role of psychological variables, particularly those of
anxiety and depression in disease progression and clinical
outcome has received attention from the research com-
munity. For example, Walker et al. [6] found in a study of
women with advanced breast cancer that anxiety and
depression, as assessed by self-report measure, were signif-
icant predictors of the patients' response to chemotherapy
in terms of clinical and pathological outcomes. Impor-
tantly, Walker and colleagues [6] identified that anxiety
and depression were independent predictors of outcome,
and therefore recommended that psychological factors
need to be assessed and evaluated within the overall con-
text of treatment.
The predictive account of the relevance of psychological
factors is further supported by the findings of other stud-
ies. Hopwood et al. [7], found that high levels of anxiety
and depression were associated with higher mortality
rates in cancer patients. Ratcliffe et al. [8], found that high
levels of depression were associated with higher mortality
rates in patients with Hodgkin's disease and non-Hodg-
kin's Lymphoma.
Given the relevance of anxiety and depression to clinical
outcome in individuals with a diagnosis of cancer, tech-
niques and tools that reliably and consistently measure
these important psychological dimensions would be wel-
comed within the therapeutic assessment and monitoring
battery. Indeed, the need for application of psychometri-
cally robust affective assessment tools to the clinical
oncology setting is pressing due to inadequate training of
non-specialist clinicians and nurses in recognising and
screening for symptoms of psychological distress [9]. This
is particularly important given the possible prognostic
advantages offered by effectively identifying those indi-
viduals who may be anxious and depressed following
diagnosis and treatment and then targeting specific inter-
ventions at these patients to reduce psychological seque-
lae [6].
In summary, there is convincing clinical evidence to sug-
gest that a psychometrically robust, accurate, easily
administered and patient acceptable affective state assess-
ment tool could be of great benefit in assessing levels of
anxiety and depression in patients with cancer.
The Hospital Anxiety and Depression Scale (HADS) [10]
is a widely used self-report instrument designed as a brief
assessment tool of the distinct dimensions of anxiety and
depression in non-psychiatric populations [11,12]. It is a
14-item questionnaire that consists of two sub-scales of
seven items designed to measure levels both of anxiety
and depression. The ease, speed and patient acceptability
of the HADS has led to it being applied to a wide variety
of clinical populations where significant anxiety and
depression may co-exist with the manifestation of physi-
cal illness [6,13-21].
The HADS has also been used widely in the clinical oncol-
ogy setting as a screening and research tool [22-28]. Inter-
estingly, conclusions drawn from investigations that have
explored the utility of the HADS in the clinical oncology
setting have yielded contradictory findings. A number of
studies have suggested that the HADS reliably measures
anxiety and depression in cancer patients [23,27,28] and
should be adopted as a routine clinical tool for screening
for psychological distress [29-31]. However, a number of
other investigations in this area have suggested that the
HADS may not be a suitable instrument to assess patients
with cancer [24,32]. A general criticism of the HADS in
cancer screening has been issues relating to the instru-
ments poor sensitivity (ability to detect true cases) and
specificity (ability to detect true non-cases) when tested
against a 'gold standard', typically, a structured clinical
interview [24,32].
However, a further issue concerns the method of scoring
the HADS in relation to the HADS anxiety (HADS-A) and
depression (HADS-D) sub-scales. A number of oncology
studies [23,26,33-35] have suggested the HADS total
score (all-14 items) should be used as a global measure of
'psychological distress'. This approach is against the rec-
ommendations of the original developers of the HADS
[10] and this practice is further reproached in the HADS
administration manual [36]. Razavi and colleagues [26]
however, based their recommendation on a psychometri-
cally robust rationale for using the HADS total score to
assess cancer patients. Based on a number of psychometric
criteria, including factor analysis and sensitivity/specifi-
city criteria this study found just one single-factor
emerged, identified as a single dimension of global psy-
chological distress. This represents a good rationale for
using the HADS as a unitary measure because it suggests
that, in this population, the HADS could not discriminate
between anxiety and depression.
However, Razavi et al.'s [26] findings of a single-dimen-
sion of global psychological distress have not been repli-
cated in other studies examining cancer. Moorey et al. [37]
found support for the bi-dimensional (anxiety and
depression) underlying structure of the HADS in cancer
patients. Interestingly, Moorey [37] did find some incon-
sistencies in their analysis with the HADS-A item 'I can sit
at ease and feel relaxed' loading onto the HADS-D sub-
scale. A further study examining anxiety and depression inPage 2 of 12
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to have an underlying three-factor structure. Lloyd-Wil-
liams [24] conducted an investigation into the utility of
the HADS in terminally ill cancer patients and found a
four-factor underlying dimensional structure.
Interestingly, a recent international consensus statement
on depression and anxiety in oncology recommended the
use of the HADS for screening cancer patients [38], how-
ever the recommendation was made on the explicit basis
that the HADS 'assesses anxiety and depression as 2
dimensions scored separately' [38].
The factor inconsistencies observed in the HADS are not
specific to studies involving cancer patients. Psychometric
anomalies in the factor structure of the HADS have been
observed in a diverse variety of clinical populations
including depression [39], coronary heart disease [17],
chronic fatigue syndrome [21], end-stage renal disease
[16] and pregnancy [14]. A recent review [11] of studies
that have investigated the underlying factor structure of
the HADS found that nearly half reported factor structures
inconsistent with the two-dimensional anxiety and
depression model proposed by Zigmond and Snaith [11].
Despite the international use of the HADS in a vast multi-
tude of clinical populations, the lack of systematic struc-
tural evaluation of the instrument in target clinical groups
has been highlighted as an important psychometric
concern.
Dunbar [40], conducted a confirmatory factor analysis of
the HADS in a non-clinical population and found support
for the three-factor tripartite model proposed by Clark &
Watson [41]. This was a theoretically important observa-
tion since Clark & Watson's [41] three-factor tripartite
model represents a development of the conceptualisation
of anxiety and depression within a coherent and evi-
denced-based model. In addition their model is based
upon a theoretically rich psychological account of anxiety
and depression which is consistent with clinical observa-
tions of the disorders. Interestingly a number of recent
psychometric investigations of the HADS have identified
a three-factor underlying structure to the HADS in clinical
populations [17,39].
Importantly, a recent investigation [21] into the psycho-
metric properties of the HADS in individuals with chronic
fatigue syndrome (CFS) tested Clark & Watson's three-fac-
tor tripartite model [41] and found it to provide a signifi-
cantly better fit to the data than the bi-dimensional model
proposed by Zigmond & Snaith [10]. McCue's [21] study
extended the observations of Dunbar et al. [40] of support
for the tripartite model to a clinical population. The rele-
vance of this is that these findings suggest that a three-fac-
tor underlying structure to the HADS may have clinical
implications since this model would be predicted by a
coherent theoretical development, that of Clark & Watson
[41], in the understanding of anxiety and depression
within a clinical context. Interestingly, a number of stud-
ies have identified a third factor in the HADS using explor-
atory factor analysis, the researchers having then deciding
to reject the third factor as meaningless and subsequently
'forcing' a two-factor solution [42,43]. It is likely that
these researchers were not expecting to find a third factor
since this would be inconsistent with Zigmond & Snaith's
fundamental premise of bi-dimensionality of the HADS
[10] and therefore chose to ignore the third factor in
favour of an anticipated two-factor solution. A more
recent study [20] used exploratory factor analysis and
found an initial three-factor structure to the HADS in
patients with end-stage renal disease. Martin and col-
leagues [20] then 'forced' a two-factor solution to their
data and then compared the forced solution with the ini-
tial three-factor solution.
These investigators found the three-factor initial solution
to be a much superior fitting underlying factor structure to
the HADS compared to the 'forced' two-factor solution. It
therefore seems possible that some researchers are in
many instances rejecting an 'unexpected' three-factor
structure in favour of the anticipated bi-dimensional
structure. This is understandable in the absence of a cred-
ible theoretical perspective that would explain the mani-
festation of a three-factor dimensional structure to the
HADS. Nonetheless, as has been established earlier, an
alternative theoretical account does exist that would, in
principle, predict a three-factor underlying structure to the
HADS; the tripartite model of Clark & Watson [41].
However, it is important to note, that a departure from the
bi-dimensional model of anxiety and depression support-
ing the HADS would suggest that the use of the HADS-A
and HADS-D sub-scales for screening purposes would be
seriously undermined since this is the fundamental
rationale for using the HADS in clinical practice [38].
Conclusions drawn from HADS-A and HADS-D sub-
scales would be unreliable, since the instrument would
not in reality be measuring anxiety and depression and
therefore clinical decision-making based on such scores
would be fundamentally flawed [14,21]. See Table 1 for a
summary of the models.
To date, no study has been conducted that has examined
the factor structure of the HADS in cancer patients by
comparing competing factor structures predicted by theo-
retical and evidenced-based accounts of psychological dis-
tress. There is a good rationale for pursuing this in cancer
patients. Given that the HADS-A and HADS-D sub-scales
have been demonstrated to have predictive outcome
potential in the clinical oncology setting [6] establishingPage 3 of 12
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HADS in this group of clients may be a clinically useful
way of improving the predictive capacity and reliability of
the instrument [40]. The first step towards this goal is to
establish the best factor structure and then undertake lon-
gitudinal research to establish the predictive value of that
structure.
Most previous factor analyses of the HADS have used
exploratory factor analysis (EFA) techniques, though there
are a small number of recent and notable exceptions to
this approach that have applied a more theoretically and
clinically relevant methodology to data called confirma-
tory factor analysis [20,21,30,40].
This study seeks to determine the appropriateness of using
the HADS as a two-dimensional instrument in women
with breast cancer by examining the instrument's underly-
ing factor structure using both EFA and CFA. The study
will test the hypothesis that the HADS comprises a two-
factor (anxiety and depression) underlying factor struc-
ture in women with breast cancer.
Methods
Design
The study used a cross-sectional design. To address the
research questions exploratory factor analysis (EFA), con-
firmatory factor analysis (CFA) and reliability analysis
methods were used using a pooled HADS data set from all
participants. Relevant clinical details were also recorded.
Statistical analysis
Reliability analysis
A reliability analysis of the HADS total all-items, and
HADS anxiety (HADS-A) and HADS depression (HADS-
D) sub-scales, was conducted to ensure that the measures
satisfied the criteria for clinical and research purposes
using the Cronbach coefficient alpha statistical procedure
[44]. A Cronbach's alpha reliability statistic of 0.70 is con-
sidered as the minimum acceptable criterion of instru-
ment internal reliability [45,46].
Exploratory factor analysis
Exploratory factor analysis was performed on the full 14-
item HADS. The criterion chosen to determine that an
extracted factor accounted for a reasonably large propor-
tion of the total variance was based on an eigenvalue
greater than 1. A maximum likelihood factor extraction
procedure was chosen on the basis that this approach is
particularly useful in extracting psychologically meaning-
ful factors [17,14,47]. A further advantage of using the
maximum likelihood approach is that a chi-square statis-
tic can be generated to determine if the number of
extracted factors offers a statistically good fit to the model
tested. An oblimin non-orthogonal factor rotation proce-
dure was chosen [47] due to the possibility that extracted
factors may be correlated. The arbitrary determination of
a significant item factor loading was set at a coefficient
level of 0.30 or greater, this level based on a rationale of
maximising the possible number of items loading on
emerging factors in order to generate a more complete
psychological interpretation of the data set, this being a
level consistent with investigators who have utilised
exploratory factor analysis [14,17,48].
Confirmatory factor analysis
Confirmatory factor analysis was conducted using the
Analysis of Moment Structures (AMOS) version 4 statisti-
cal software package [49]. Seven models derived from
clinical and empirical research were tested. These were
Zigmond & Snaith's original two-factor model [10], Moo-
rey et al.'s two-factor model [37], Razavi et al.'s single-fac-
tor model [26], Clark and Watson's three-factor tripartite
model [41], Clark and Watson's three-factor hierarchical
tripartite model [41] Friedman et al.'s three-factor corre-
lated model [39] and Brandberg et al.'s three-factor corre-
lated model [22].
Table 1: Characteristics of each factor model tested
Model No. Factors Population n Extraction 
method
FLI1** FLI2 FLI3
Zigmond et al(1983) 2 Medical 100 None 1,3,5,7,9,11,13 2,4,6,8,10,12,14 ----
Moorey et al. (1991) 2 Cancer 568 PCA 1,3,5,9,11,13 2,4,6,7,8,10,12,14 -----
Dunbar et al (2000) 3 Non-clin 2,547+ CFA 1,5,7,11 2,4,6,7,8,10,12,14 3,9,13
Friedman et al. (2001)* 3 Depressed 2,669 PCA 1,7,11 2,4,6,8,10,12,14 3,5,9,13
Razavi et al. (1990) 1 Cancer 210 PCA All items --------- ---------
Brandberg et al. (1992) 3 Cancer 273 PCA 3,5,9,13 2,4,6,8,10,12 1,7,11,14
*The three-factors are correlated in this model. +Based on CFA of three independent samples of N = 894, 829 and 824, the total cohort in this 
study is 2,547.
#PCA: Principal Components Analysis; CFA: Confirmatory Factor Analysis. **FLI: Factor Loading Items. The HADS items loading on each model 
tested.Page 4 of 12
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and the maximum likelihood method of estimation was
used. Factors were allowed to be correlated where this was
consistent with the particular factor model being tested.
Multiple goodness of fit tests [50] were used to evaluate
the seven models, these being the Comparative Fit Index
(CFI) [51], the Akaike Information Criterion (AIC) [52],
the Consistent Akaike Information Criterion (CAIC) [53]
and the Root Mean Squared Error of Approximation
(RMSEA). A CFI greater than 0.90 indicates a good fit to
the data [54]. A RMSEA with values of less than 0.08 indi-
cates a good fit to the data, while values greater than 0.10
suggest strongly that the model fit is unsatisfactory. The
AIC and CAIC are useful fit indices for allowing compari-
son between models [40]. The Chi-square goodness of fit
test was also used to allow models to be compared and to
determine the acceptability of model fit. A statistically sig-
nificant χ2 indicates a proportion of the variance in the
model remains unexplained by the model tested [50].
Comparison with normative data
Comparison with the most contemporary normative
HADS data in breast cancer patients [55] was conducted
using the one-sample t-test.
Procedure
An information sheet and consent form was posted to
patients approximately three weeks prior to their routine
clinic follow-up. Participants were either seen at home or
at clinic by one of the researchers (RM) and completed a
pack of questionnaires including the HADS. Participants
also completed a short neurocognitive test battery. The
study took 45 minutes to complete.
Participants
110 women who had undergone adjuvant treatment for
breast cancer, and were at least 6 months post-chemother-
apy, participated in the study. Patients with a history of
major psychiatric illness were excluded. Women were
recruited from three treatment groups: chemotherapy
alone, hormonal therapy alone, and a combination of
chemotherapy and hormonal therapy.
Socio-demographic and treatment characteristics of the
participant groups are presented in Table 2. A significant
group effect of age was observed, F(2,107) = 3.09, p = 0.05,
with women in the hormone therapy alone group being
significantly older than women in the chemotherapy
alone group (Bonferroni post-hoc test, p = 0.04). No other
statistically significant differences were observed between
groups, all further group comparisons of socio-demo-
graphic, baseline treatment data and HADS-A and HADS-
D scores being conducted using analysis of co-variance
(ANCOVA) controlling for age.
The data was drawn from a larger study exploring neuro-
cognitive and behavioural outcomes following breast can-
cer treatment. Ethical approval was obtained from
Newcastle and North Tyneside Health Authority Joint Eth-
ics Committee. Participants were recruited through the
Northern Centre for Cancer Treatment and the Royal
Victoria Infirmary, Newcastle upon Tyne, UK. Written
informed consent was obtained from all participants prior
to the commencement of the study.
Results
The mean scores of participant's ratings on the HADS-A
were 7.43 (SD 4.14) and HADS-D was 3.25 (SD 2.97).
Using Snaith & Zigmond's interpretation of HADS-A and
HADS-D scores of 8 or over, 51 participants (46.4%) dem-
onstrated possible clinically relevant levels of anxiety and
11 patients (10.0%) possible clinically relevant levels of
depression [10]. Adopting Snaith & Zigmond's higher
threshold for sensitivity of HADS-A and HADS-D scores of
11 or over, 24 participants (21.8%) demonstrated proba-
ble clinically relevant levels of anxiety and 3 participants
(2.7%) probable clinically relevant levels of depression
[36].
Table 2: Demographic and clinical data mean scores/levels with standard deviations in parentheses and accompanying F and p values of 
group comparisons.
Group type
Variable Chemotherapy alone Chemotherapy and 
hormone
Hormone alone F p
HADS-A 7.33 (3.99) 6.48 (3.96) 7.35 (4.90) 0.08* 0.92
HADS-D 3.11 (3.73) 2.90 (2.30) 4.35 (3.35) 1.95* 0.15
Length of time since treatment ended 2.49 (2.09) 2.53 (1.56) 1.83 (1.43) 1.69* 0.19
Townsend index of deprivation -0.78 (2.76) -0.94 (3.10) 0.37 (3.46) 1.20* 0.30
Age 52.52 (8.20) 55.24 (6.86) 57.95 (9.06) 3.09# 0.05
*Analysis of co-variance (ANCOVA) controlling for age, F(2,106) degrees of freedom.
#Analysis of variance (ANOVA), F(2,107) degrees of freedom.Page 5 of 12
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Calculated Cronbach's alpha of the HADS (all 14 items),
HADS-A and HADS-D sub-scales was 0.85, 0.79 and 0.87
respectively, exceeding Kline's criterion for acceptable
instrument internal reliability [45].
Comparison with normative data
No statistically significant differences were observed
between HADS-A (t(109) = 0.18, p = 0.85) and HADS-D
(t(109) = 0.16, p = 0.87) mean scores of the current study
compared to those of Osborne et al. [55].
Exploratory factor analysis
The Kaiser-Meyer-Olkin (KMO) measure of sampling ade-
quacy and the Bartlett Test of Sphericity (BTS) were con-
ducted on the data prior to factor extraction to ensure that
the characteristics of the data set were suitable for the fac-
tor analysis to be conducted. KMO analysis yielded an
index of 0.86, and in concert with a highly significant BTS,
χ2(df = 91) = 635.36, p < 0.001, confirmed that the data dis-
tribution satisfied the psychometric criteria for the factor
analysis to be performed. Following factor extraction and
oblimin rotation, three factors with eigenvalues greater
than 1 emerged from analysis of the complete HADS and
accumulatively accounted for 59.82% of the total vari-
ance. The factor loadings of the individual HADS items in
relation to the three-factor solution are reproduced in
Table 2.
Factor scores on each extracted factor for each participant
were calculated using regression. In contrast with the Bar-
tlett and Anderson-Rubin methods of factor score calcula-
tion, the regression method was chosen since this
technique does not assume the extracted factors are
orthogonal and also minimises any sum of squares dis-
crepancies between true and estimated factors over indi-
viduals. Factor one proved to be highly statistically
significantly, but negatively correlated with factor two, r =
-0.48, p < 0.001. Factor one was significantly positively
correlated with factor three, r = 0.45, p < 0.001. Factor two
was observed to be highly statistically and negatively cor-
related with factor three, r = -0.63, p < 0.001. The chi-
square goodness of fit test, χ2(df = 52) = 57.18, p = 0.29, was
not statistically significant suggesting that the three-factor
solution extracted provided a good fit to the data. A forced
two-factor solution was then specified, however, the
emergent factor solution failed to provide a good fit to the
data, χ2(df = 64) = 85.62, p = 0.04. The forced two-factor
solution accounted for only 45.08% of the total variance.
Confirmatory factor analysis
The factor models tested and accompanying fit indices are
shown in Table 3. The χ2 goodness of fit analyses for all
models were statistically significant (p < 0.05) indicating
a proportion of the variance was unexplained by each
model. Examination of the fit indices for each model
revealed that the best fit to the data is Clark and Watson's
[41] three-factor tripartite model, their being little differ-
ence between correlated and hierarchically correlated ver-
sions of the model (Figure 1). The second closest fit to the
data was provided by Friedman et al.'s three factor model
[39]. The third closest fit to the data was found to be
Brandberg et al.'s [22] three-factor correlated model. Zig-
mond and Snaith's original two-factor model [10] offered
the fourth best fit to the data, while the two-factor model
of Moorey et al. [37] provided the fifth best fit. The worst
fit to the data was furnished by the single factor model of
Razavi et al. [26](Table 4).
Table 3: Factor loadings of HAD Scale items following maximum likelihood factor extraction with oblimin rotation
HAD Scale item Factor 1 Factor 2 Factor 3
Anxiety sub-scale
(1) I feel tense or wound up 0.17 -0.30 0.45
(3) I get a sort of frightened feeling as if something awful is about to happen 0.16 -0.80 -0.08
(5) Worrying thoughts go through my mind 0.24 -0.55 0.16
(7) I can sit at ease and feel relaxed 0.26 -0.10 0.61
(9) I get a sort of frightened feeling like 'butterflies' in the stomach -0.18 -0.79 0.04
(11) I feel restless as if I have to be on the move -0.06 0.01 0.53
(13) I get sudden feelings of panic 0.03 -0.82 0.04
Depression sub-scale
(2) I still enjoy the things I used to enjoy 0.72 -0.04 -0.02
(4) I can laugh and see the funny side of things 0.50 -0.11 0.12
(6) I feel cheerful 0.45 -0.15 0.15
(8) I feel as if I am slowed down 0.56 0.07 0.18
(10) I have lost interest in my appearance 0.35 -0.01 -0.05
(12) I look forward with enjoyment to things 0.88 -0.08 -0.11
(14) I can enjoy a good book or TV programme 0.58 0.07 0.01
*Bold indicates that item loading on a factor is 0.30 or abovePage 6 of 12
(page number not for citation purposes)
Health and Quality of Life Outcomes 2005, 3:41 http://www.hqlo.com/content/3/1/41Discussion
This study has yielded interesting and clinically pertinent
observations regarding the HADS in relation to psycho-
logical screening in women with breast cancer. The find-
ing of relatively high levels of anxiety (mean = 7.43) and
low levels of depression (mean = 3.25) is entirely consist-
ent with the most recent investigation reporting HADS
normative anxiety (mean = 7.50) and depression (mean =
3.30) data in a relatively large (N = 731) population of
women with breast cancer [55]. This finding is suggestive
that the HADS-A and HADS-D sub-scales appear to be
pathology specific and sensitive.
Estimations of internal reliability revealed Cronbach's
alpha's of the HADS (all items) and the HADS-A and
HADS-D sub-scales to be all statistically acceptable,
indeed, these observations being entirely consistent with
previous research into the psychometric properties of this
instrument (Bjelland et al., 2002). The HADS-A and
HADS-D sub-scales were found to be positively and statis-
tically significantly correlated, an observation that is again
consistent with previous research [11]. Taken together, the
consistency of HADS-A and HADS-D scores between this
study and normative breast cancer HADS scores, the good
internal reliability of HADS-A and HADS-D sub-scales
and confirmation of the anticipated significant positive
correlation between HADS-A and HADS-D sub-scales sug-
gests that the HADS has achieved a number of the psycho-
metric credentials required to confer it's acceptability as a
reliable and valid screening tool of anxiety and depression
for use in women with breast cancer.
However, the results of the EFA and CFA add a further
dimension to the debate over the psychometric integrity
of this instrument in this clinical population and, indeed,
provide compelling evidence that the assumed bi-dimen-
sional anxiety and depression underlying structure of the
HADS should be reviewed, particularly in patients with
breast cancer.
The EFA of the HADS revealed an initial three-factor
underlying structure which provided a good fit to the data.
When compared to a forced two-factor solution, the ini-
tial three-factor model provided a better fit to the data, the
two-factor forced solution offering a statistically poor fit
to the data. This is a clinically pertinent observation since
not only does this finding reveal that the HADS does not
measure two distinct dimensions of anxiety and depres-
sion in this population, it informs the growing evidence
base which has increasingly suggested that the HADS is
not a reliable measure of anxiety and depression when
used within the context of a wide range of pathology
[14,20-22,26,39,56].
Examination of individual item loadings is illuminating.
It was observed that the HADS-A sub-scale items 1. 'I feel
tense or wound up', 7. 'I can sit at ease and feel relaxed'
and 11. 'I feel restless as if I have to be on the move'
loaded on extracted factor 3. This separation of HADS-A
items has been observed previously in factor analysis of
cancer patient data.
Brandberg et al. [22], in a study of patients with malignant
melanoma (skin cancer), found a three factor structure to
the HADS and identified a 'restlessness' factor comprising
items 1, 7, 11 and 14. Item 14. 'I can enjoy a good book
or TV programme' was not found to load on to the
'restlessness' factor reported by Brandberg and colleagues
[22] in the current study, though with this exception, the
loading of HADS-A items on this 'restlessness' factor is
identical. Items 3. 'I get a sort of frightened feeling as if
something awful is about to happen', 5. 'Worrying
thoughts go through my mind', 9. 'I get a sort of
frightened feeling like 'butterflies' in the stomach' and 13.
'I get sudden feelings of panic' loaded onto extracted fac-
tor three. This observation, is consistent, indeed identical,
with that factor extracted and observed by Brandberg et al.
(1992) and termed 'anxiety'. Item 1. 'I feel tense or wound
up' was observed to also load onto factor 2, however it
Table 4: Factor structure of the HADS determined by testing the fit of models derived from factor analysis.
Model χ2 df p RMSEA CFI CAIC AIC
Zigmond and Snaith two-factor 121.77 (76) 0.001 0.07 0.92 287.08 179.77
Moorey et al. two-factor 132.16 (76) <0.001 0.08 0.90 297.47 190.16
Friedman three-factor correlated 101.79 (74) 0.018 0.06 0.95 278.50 163.79
Dunbar et al. three-factor tripartite 96.16 (73) 0.036 0.05 0.96 278.57 160.16
Dunbar et al. three-factor hierarchical tripartite 96.27 (73) 0.035 0.05 0.96 278.68 160.27
Razavi single-factor 212.22 (77) <0.001 0.13 0.77 371.83 268.22
Brandberg et al. three-factor 116.11 (74) 0.001 0.07 0.93 292.83 178.11
The best fit to the data is provided by the three-factor tripartite model and the three-factor hierarchical tripartite model of Clark & Watson (1991) 
based on Dunbar et al. (2000).Page 7 of 12
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on extracted factor 3. All the HADS-D items loaded onto
factor 1, this extracted factor being consistent with the
depression sub-scale these items are designed to measure.
The findings from the EFA would suggest that the HADS is
comprised of three underlying factors, these being depres-
sion, anxiety and restlessness.
The CFA both supports the findings of the EFA and pro-
vides further evidence to support the notion that the
HADS is comprised of an underlying three-factor structure
in breast cancer patients. It should be noted that, though
the χ2 analysis of all models tested were statistically signif-
icant, indicating a significant proportion of the variance of
the model tested to be unexplained in the data, it is readily
acknowledged that trivial variations in the data can lead to
significant χ2 test results [57] and therefore the usefulness
of the test within the realm of CFA is that it provides an
index of comparatively how well a model fits the data. The
three-factor models tested proved to provide better fits to
Clark & Watson's (1991) Tripartite model applied to HADS dataFigure 1
Clark & Watson's (1991) Tripartite model applied to HADS data. Note: Figures represent standardised parameter 
estimates.
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ally all indices of model fit. The single factor model tested
revealed the poorest fit to the data of all the models.
Clark & Watson's [41] three-factor tripartite and three-fac-
tor hierarchical tripartite models [40] provided the best fit
to the data, examination of the RMSEA and CFI fit tests
revealing that these three-factor models satisfied the crite-
ria for a good fit to the data. Interestingly, the participant
population in Dunbar et al.'s study [40] was drawn from
a non-clinical population and the basis for the study was
to test a strong contemporary theoretically-based account
of anxiety and depression, that of Clark & Watson [41].
The second best fit to the data (Clark & Watson's model fit
being virtually identical will be treated as a single best fit
model) was provided by Friedman et al.'s three-factor
model [39]. Friedman et al.'s study was an EFA on HADS
data from a psychiatric population, individuals being
treated for depressive disorder [39]. This finding gives an
indication to the possibility that the three-factor best
model fit observed in the current study may not, essen-
tially be related to the presenting pathology, since breast
cancer and depressive disorder represent two distinct and
aetiologically unrelated clinical presentations, therefore
the superior (compared to the competing two-factor mod-
els tested) three-factor model fit of Friedman's model [39]
may, in fact, be tapping into the basic fundamental factor
structure of the HADS.
This observation would be supported by the findings of
the model fit of Brandberg's three-factor model [22],
superior to that of the two-factor models. Observation of
an underlying three-factor structure to the HADS has been
observed in a number of other studies investigating a
broad spectrum of clinical and non-clinical populations
[16,20,21]. There have also been a number of instances in
studies of psychiatric disorder where a three-factor under-
lying structure to the HADS has been initially observed
and has then been dismissed by the authors in favour of
the (presumably) expected two factor solution [42,43].
Arguably and retrospectively, these studies suggest further
support for a three-factor underlying structure to the
HADS.
Brandberg et al. [22] commented that, in spite of finding
support for a three-factor underlying structure to the
HADS, there was not a need for a revision of the instru-
ment, rather, it was suggested that further studies of the
instrument should be conducted. It is now over ten years
since Brandberg and colleagues study [22] and the accu-
mulating evidence base concerning the factor structure of
the HADS raises credible clinical issues regarding the util-
ity of this instrument across a range of pathologies. The
findings from the CFA in the current study revealed that
the two-factor models tested [10,37] offered a poorer fit to
the data compared to the three-factor models. However, it
should be stressed that examination of the RMSEA and
CFI of both these two-factor models revealed that they
offered an acceptable fit to the data. This is a noteworthy
observation since other studies which have found support
for the three-factor model of the HADS have found evi-
dence that two-factor models offer a very poor fit to the
data [20,21]. In summary, the CFA findings from the cur-
rent study support a three-factor underlying factor struc-
ture to the HADS, though poorer fitting two-factor models
still provide an acceptable, albeit less so, fit to the data.
Two questions remain, firstly what is the HADS measur-
ing within the context of a three-factor model and sec-
ondly, should the HADS be continued to be used as a bi-
dimensional screening tool for the detection of individu-
als experiencing anxiety and depression?
The best fit to the data was provided by Clark & Watson's
tripartite and hierarchical tripartite three-factor models
[41], there being very little difference between the models
statistically establishing that both models are measuring
fundamentally the same constructs. According to Clark &
Watson's [41] formulation of anxiety and depression, the
three factors observed in the HADS would represent dis-
tinct dimensions of negative affectivity, autonomic anxi-
ety and anhedonic depression. These theoretically derived
models have been shown to provide a best fit to the data
in two previous research investigations that have focused
on both a non-clinical populations [40], and a clinical
population of individuals with chronic fatigue syndrome
[21]. Furthermore, Crawford et. al [58] in a study evaluat-
ing the reliability ad validity of the Positive and Negative
Affect Schedule (PANAS) and its relationship with other
measures of depression and anxiety including the HADS
have recently provided further support for tripartite theory
of anxiety and depression.
It must be acknowledged that a number of limitations will
inevitably apply to the current study. It must be noted that
the sample size for the study was borderline for conduct-
ing SEM with AMOS but was adequate by a number of
conventional criteria. One must also take into account the
suggestion that differing methodologies used across stud-
ies to undertake factor analysis may account for the differ-
ences found, see Martin [58] for a full discussion of these
issues. Additionally the low mean depression scores for
the sample, whilst consistent with other studies with sim-
ilar populations, might result in the presence of a floor
effect, thus limiting the variance within the sample. This
may have resulted for the fact that in order to avoid the
short term acute sequelae associated with intensive
treatment all participants were at least two years from
treatment at the time of the investigation.Page 9 of 12
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[40] and McCue et al. [21] to a further population with
distinct pathology. It has been suggested by Dunbar [40]
that by using the hierarchical tripartite model, the auto-
nomic anxiety and anhedonic depression factors would
be of greater value in discriminating between anxiety and
depression than simply using HADS anxiety and depres-
sion sub-scale scores. Brandberg et al. [22] noted that the
HADS-D sub-scale was the most useful for clinical pur-
poses, though the rationale was not stated, it seems plau-
sible to assume that this was because of the 'split' HADS-
A sub-scale observed in their factor analysis. This observa-
tion is entirely consistent with that of Dunbar [40] who
suggests a convincing rationale why the HADS is not a
highly discriminative instrument in some populations is
because the HADS-A and HADS-D sub-scale scores are
contaminated by overlap between the three underlying
factors. A method of significantly increasing discrimina-
bility has been suggested by Dunbar et al., [40] involving
regressing autonomic anxiety and anhedonic depression
factors scores on to the negative affectivity (third factor)
sub-scale scores.
A further study would be required to establish the efficacy
and desirability of this approach since comparison of fac-
tor derived scores would need to be compared against a
gold standard such as a formal structured clinical inter-
view schedule. Using this approach receiver operating
characteristic (ROC) curves could be calculated to
evaluate any relative improvement of regressed auto-
nomic anxiety and anhedonic depression scores com-
pared to HADS-A and HADS-D scores.
The RMSEA and CFI statistics revealed that the two-factor
models tested offered acceptable fits to the data, with Zig-
mond & Snaith's original two-factor formulation [10]
offering a slightly better fit to the data to that of Moorey et
al.'s modified two-factor model [37]. It is worthy of com-
ment that Zigmond & Snaith's [10] model was superior to
that of Moorey et al.'s model [37], in spite of the latter
researchers using a clinical cohort comprised exclusively
of cancer patients. This observation offers further support
to conclusions drawn from the three-factor models tested
that the underlying factor structure of the HADS is rela-
tively stable and the impact of pathology on the factor
structure of the instrument may be relatively minor. One
of the central tenet for supporting using the HADS is that
it is easy to use, this of course, includes scoring the instru-
ment. Whether, any significant benefits in discriminabil-
ity that may be identified in using the regressed scores as
suggested by Dunbar et al. [40] may be off-set by an
increase in sophistication in terms of calculating regressed
factor scores in clinical practice.
Obviously, this is an area for future investigation, how-
ever it is worth noting that a wide variety of health profes-
sionals use the HADS in clinical practice on an everyday
basis and it is these individuals who may feel reluctant or
lack the time to calculate regressed scores for the HADS
unless there is a large improvement to be found in the
instruments accuracy by doing so. A simple scoring algo-
rithm would be a fundamental requirement if the
approach suggested by Dunbar and colleagues [40] was to
move from the arena of academic and clinical research
into the natural environment for the HADS, everyday clin-
ical practice.
On balance, and incorporating the above limitations of
ensuring that the HADS remains an easy to use clinical
screening instrument, it is suggested that HADS remains a
useful screening instrument in the clinical oncology envi-
ronment and may be scored and interpreted in the recom-
mended manner [10,36]. However, further clinical
research work is recommended in this area to determine if
scoring the instrument as a three-factor measure offers any
worthwhile benefits in case detection that may offset a
more complicated scoring procedure. No evidence at all
was forthcoming to suggest that the HADS should be used
as a one-dimensional model of global psychological dis-
tress, the single factor model providing a very poor fit to
the data. Based on this observation it is suggested that a
total HADS score should not be used in this clinical
context.
Conclusion
In conclusion, a compromise is suggested based on the
clinical research observations of the current study and the
clinical context of everyday professional practice where
the HADS is used as a screening instrument of choice. The
HADS was found to have an underlying three-factor struc-
ture in breast cancer patients. The possibility that
improved accuracy in case detection may be found by
using a three factor model to score the HADS is balanced
by a potential decrease in the ease of use of the instrument
because a more complex scoring system will be required.
This issue can be settled by future research in this area to
determine the magnitude of any worthwhile clinical gains
in scoring the HADS as a three-factor instrument. Cur-
rently however, it is suggested that the HADS can be con-
tinued to be used and scored in the traditional way, since
the two-factor models tested still provided an acceptable
fit to the data. However, it is recommended that for
screening purposes with breast cancer patients, verifica-
tion of borderline level scores should be established by a
structured diagnostic clinical interview. Those using the
HADS in clinical practice may also wish to consider using
further measures of negative affectivity and autonomic
anxiety, since these are currently poorly represented in thePage 10 of 12
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the HADS, may be more usefully developed as a three-
dimensional rather than bi-dimensional tool consistent
with advances in psychological models of anxiety and
depression [41] should not be ruled out.
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